Cephalon offer for Arana now unconditional
This article was originally published in Scrip
Cephalon's A$1.40 ($1.10) per share offer for the Australian antibody firm Arana Therapeutics has been declared final and unconditional, and is set to close on June 1st, unless extended. The move now means that Cephalon cannot increase the offer price, although it will rise to $1.45 per share if the US firm secures a holding of at least 90% during the offer period. It now holds a 53.4% stake. Arana shareholders will actually receive five cents a share less on settlement of the A$318 million acquisition, to adjust for a special five cent dividend already paid.
You may also be interested in...
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.